Validation of Ballistocardiographic Biosensors and Other Hemodynamic Measures for Healthy Subjects

计划入组 20 人 · 首次发布于 2020 年 10 月 14 日

Validation of New G6PD Point of Care Tests Against Gold Standard Quantitative

计划入组 150 人 · 首次发布于 2015 年 12 月 9 日

Molecular Biosensors for Detection of Bladder Cancer

计划入组 230 人 · 首次发布于 2016 年 11 月 6 日

Menotropin biosimilar (Klarvoyant Biogenics)

Urofollitropin biosimilar (Klarvoyant Biogenics)

Autologous osteoblastic cell therapy(BioSenic)

BioMendics, LLC

United States

Biosensors Europe SA

Belgium

BIOGENICS PTY LTD

Australia

Wearable Tech Shows Promise in Monitoring CMT Disease Progression for Clinical Trials

BioSenic Advances Autoimmune Pipeline and Explores Strategic M&A Opportunities

FDA Grants Fast Track Designation to BioMendics' TolaSure Gel for Epidermolysis Bullosa Simplex